



Apiam Animal Health Ltd

20th Australasian AgFood Conference

Sustainability & scalable cash flow

31 May 2022



Apiam Animal Health snapshot



SCAN ME

- ➔ **Unique ASX-listed veterinary business**
- ➔ **Diversified business model** with a rural and regional focus
 - servicing whole spectrum of production & companion animals
 - clinics located in fast-growing regional locations
- ➔ **Attractive financial profile** with revenue growth, earnings margin expansion and strong operating cash flows
- ➔ **Strong industry outlook** for regional veterinary markets
- ➔ **Accelerated growth strategy** via acquisitions, organic initiatives & greenfield clinic roll-out program (10 acquisitions in FY22 YTD)



70

CLINICS*



260+

VETERINARIANS



70%

DAIRY & MIXED
ANIMAL CLINIC
CONTRIBUTION

Diversified & resilient vet services portfolio

MIXED ANIMAL & DAIRY SEGMENT (COMPANION ANIMALS INCL. EQUINE)



70%
of H1 FY22
revenues

- Service regional cities and towns
- Veterinary clinical services
- Wellness programs
 - Best Mates program
 - ProDairy program
- Extensive range of product sales
 - prescription, private label, exclusive, retail
- Dairy-integrated product supply chain
- Diagnostics and Pathology
- Feed testing & Parasitology

BEEF FEEDLOT & PIG SEGMENTS (INTENSIVE LIVESTOCK ANIMALS)




30%
of H1 FY22
revenues

- Service specialised industries across Australia
- Veterinary consulting services
- Extensive range of product sales
 - incl. vaccines, prescription, private label
- Integrated product supply chain
- Genetic services
- Diagnostic Laboratory
- Vaccine Laboratory
- Feed testing
- Data Analysis Platforms



Aplam's vertically integrated model



Strategy to double revenue to \$300M by FY24

REVENUE GROWTH DRIVERS

Organic growth

- Regional veterinary industry growing rapidly
- Industry outlook for intensive animals improving
- Capture further dairy & mixed animal market share
- Track-record of product & service development
- Product innovation opportunities underway with significant market potential

Acquisition pipeline


- Extensive acquisition pipeline following vet industry restructure with many opportunities in due diligence
- Track record of M&A execution and integration with 20 acquisitions since IPO
- Investment in H1 FY22 to bolster acquisition support teams & resources within head office
- Well-funded to execute opportunities

Greenfield sites

- Greenfield sites to reach financial maturity
- \$3M revenue target per greenfield site within 3 years of opening

Revenue target of \$300M+ in FY24

Planned revenue growth trajectory



Building a sustainable future



Environmental

- Solid progress of Antimicrobial Stewardship Strategy in FY22
- Developing new vaccines to reduce antibiotic usage and improve production efficiency
- Antibiotic Resistance testing program in place
- On track to launch our Corporate Sustainability Strategy in FY22
- Implementing a solar-based Virtual Power Network across key sites



Social

- Embracing flexible workplace arrangements
- Implemented Mental Health strategy with 51 Mental Health First Aid Officers across clinic network
- Additional employee leave day to support mental health
- Partnership with Smiling Mind to support wellbeing
- Introduced Tele-triage platform to reduce vet after hours
- Fur Life Foundation provided over \$150,000 to Rural Aid and wildlife shelters
- Implemented VetFlix online training platform




Governance

- Introduced Remuneration Policy to enhance gender pay equity
- Reviewed Diversity Policy and set measurable diversity objectives
- Developed Nurse Skills Matrix to enhance professional development
- Modern Slavery Statement released in March 2021



Autogenous (custom) vaccines

STRONG UNMET MARKET DEMAND FOR AUTOGENOUS VACCINES AS PATHOGENS CONTINUE TO EVOLVE



- Used when commercial vaccines are not available or not effective
- Available under veterinary prescription & manufactured under a permit
- Apiam have 10 existing permits for **bacterial** vaccines targeting pathogens that affect pigs, poultry, sheep and cattle
- Valuable tool that has been successfully used in preventative health programs to reduce usage of antimicrobials
- New gene sequencing technologies to enhance vaccine effectiveness
- Integration with 'high tech' diagnostic services, antimicrobial resistance surveillance and usage data analysis enhancing One Health objectives



Innovation in products



UNIQUE VACCINE FOR FEEDLOT CATTLE

- APVMA approval received to manufacture *Histophilus somni* vaccine for cattle, sheep & goats
- To be manufactured locally at Apiam's ACE Laboratories facility
- First for Australian livestock industry
- Misunderstood pathogen – can cause high levels of mortality & morbidity in intensively raised cattle
- Currently treated with antibiotics
- Third new vaccine since ACE acquisition in Dec 2019
- New technologies employed can be applied across entire Apiam autogenous vaccine portfolio

REGULATORY APPROVAL TO LAUNCH XTEND 21® IN US

- Distribution partnership with Aurora Pharmaceutical
- Aurora Pharmaceutical has US EPA notice to market Xtend 21® Antimicrobial Surface Protectant (Zoono Microbe Shield technology)
- Extensive trials in global markets demonstrate efficacy against economically significant livestock pathogens
- Iowa State University demonstrated 21 days enhanced surface protection
- Antimicrobial stewardship innovation within animal health segment
- Aurora is a leading US veterinary pharmaceutical player
 - 10K veterinary customers
 - Supplies 20 specialist products
 - Extensive technical sales network



March 2020

License agreement with Zoono Animal Health



Distribution agreement with Aurora Pharmaceutical



2HFY20 & FY21

Extensive third-party trials of Zoono Microbe Shield technology (Xtend 21®)

Oct 2021

US EPA notice provided to enable launch of Xtend 21®

March 2022

Commencement of market launch of Xtend 21®

Development of new vaccines against viruses

GOVERNMENT GRANT SECURED TO BUILD NEW LEADING VIRAL VACCINE LABORATORY FOR ANIMAL HEALTH



- Apiam awarded \$700K through Victorian Government *Regional Jobs Fund*
- Funding will enable Apiam to fast-track development of new state-of-the-art **viral** vaccine facility in Bendigo to complement our existing **bacterial** vaccine laboratory
- Locally-produced autogenous viral vaccines will fill a critical gap in Australia's animal health market
- New pathogens continue to evolve and are predicted to be an ongoing issue for livestock
- Future export market potential in New Zealand (already supply bacterial vaccines)
- Work underway towards priority vaccines (in conjunction with University research partners)




Antimicrobial Stewardship



DATA SYSTEM FOR
SWINE HEALTH &
PRODUCTION



- Enhances antimicrobial stewardship
- Records and benchmarks antibiotic use
- Improves quality assurance systems
- Pilot program completed in Australia
- Currently early-stage commercialization across Australian pig industry
- Pilot program commenced with US pig industry for completion in December 2022



PRG DAIRY

- Enhances antimicrobial stewardship
- Diagnostics improve decision making processes
- 75% growth in dairy farm enrollments in H1 FY22 (vs pcg)
- ~15.0% of AU's dairy cows are enrolled in the program (compared to ~8% in PCP)
- Services supporting a buoyant industry with focus on milk quality



Employer of choice



MARKET LEADING HR PRACTICES

To attract the best talent Apiam offers the following benefits:

- ✓ A wide variety of leadership roles
- ✓ Significant opportunity for flexible work practices
- ✓ Strong culture of recognising female talent
- ✓ Flexible path to promotion
- ✓ Continuous education focus
- ✓ Recognition and rewards programs
- ✓ Mental health support



TELE-TRIAGE INITIATIVE

Introduced in FY21 to address work-life balance issues for regional vets:

- ✓ After hours calls taken by experienced virtual support team
- ✓ Incidents triaged to ensure best practice response to emergency care and other non-critical matters
- ✓ Proprietary software system developed to allocate appropriate resources and ensure best practice veterinary services
- ✓ Reduction in vet after hours calls by over 60% since deployment.
- ✓ Initiative assisting in recruitment and retention of vet workforce





Scalable cash flow & earnings

Apiam has a strong track record of earnings to cash flow conversion, with key drivers of growth over the next year being:

- Further operational leverage from acquisitions executed in H1 FY21 + FY22
- Optimisation of business mix
 - greater contribution of less-cyclical and higher margin dairy & mixed animal segment
 - product & service innovation in intensive animal segment
- Maturity of greenfield sites opened last 12 months
- Disciplined cost control and operating expense spend

Operating cash flow performance



Summary

- Regional veterinary markets growing strongly
- Apiam is capturing growth via organic initiatives and accelerated acquisition program
- On-track to double base revenues by FY24 to more than \$300M
- Well-funded to execute on strategy
- Scalable earnings and cash flows with business support infrastructure in place
- Building a sustainable future – innovation for our customers, employees and shareholders





QUESTIONS & FURTHER INFORMATION:

Dr Chris Richards
Managing Director
Apiam Animal Health Limited
chris@apiam.com.au

Catherine Ross
Investor Relations
catherine.ross@apiam.com.au
0421 997 481

This announcement was authorised by the Board
of Directors of Apiam Animal Health Limited



Disclaimer

DISCLAIMER

The information presented to you by Apiam Animal Health Limited ACN 604 961 024 (**Company**) in this presentation and any related documents (together, **Materials**) has been prepared for information purposes only and is not an offer or invitation to acquire or dispose of shares in the Company, nor shall it be relied on in connection with any investment decision.

NO FINANCIAL ADVICE

The information contained in the Materials has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Nothing in the Materials constitutes as financial advice. Before making any investment decision, you should consider, with or without the assistance of a financial advisor, whether an investment is appropriate in light of your particular investment needs, objective and financial circumstances.

NO LIABILITY

The Company has prepared the Materials based on information available to it at the time of preparation, from sources believed to be reliable and subject to the qualifications in the Materials. To the maximum extent permitted by law, the Company, its related bodies corporate and their respective officers, employees, representatives, agents or advisers accept no responsibility or liability for the contents of the Materials. No representation or warranty, express or implied, is made as to the fairness, accuracy, adequacy, validity, correctness or completeness of the information, opinions and conclusions contained in the Materials.

PAST PERFORMANCE

Past performance information contained in the Materials is given for illustration purposes only and should not be relied upon as (and is not) an indication of future performance. Actual results could differ materially from those referred to in the Materials.

FORWARD LOOKING STATEMENTS

The Materials contain certain 'forward looking statements'. These statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause the actual results, performance or achievement of the Company to be materially different from future results, performance or achievements expressed or implied by those statements.

These statements reflect views only as of the date of the Materials. The actual results of the Company may differ materially from the anticipated results, performance or achievement expressed, projected or implied by these forward looking statements. Subject to any obligations under the Corporations Act, the Company disclaims any obligation to disseminate any updates or revision to any forward looking statement to reflect any change in expectations in relation to those statements or any change in circumstances, events or conditions on which any of those statements are based.

While the Company believes that the expectations reflected in the forward looking statements in the Materials are reasonable, neither the Company nor any other person gives any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward looking statements in the Materials will actually occur and you are cautioned not to place undue reliance on any forward looking statements.




Appendix

Rapid regional veterinary market growth


- ✓ Net migration to regional areas is the highest on record
- ✓ Significant increase in pet and livestock ownership continuing post COVID-19
- ✓ Increasing spend per household on vetcare
- ✓ Apiam's broad animal expertise aligned with regional vet offering – different to metro models
- ✓ La Niña & post-drought conditions supporting strong pasture-based livestock industries (dairy, beef, sheep, equine)
- ✓ Rapid regional growth and vet industry dynamics resulting in high quality acquisition pipeline

Net internal migration (cities to regions)




15%
growth in
household pet
ownership since
2019¹

Australian avg rainfall (rolling average)




Median rainfall forecast (Dec 21 – Feb 22)



Financial track record last 4 years


Revenue (\$m)



Gross profit (\$m) & margin (%)



Underlying EBITDA (\$m)



- **Resilient revenue growth** over past 4 years despite varied industry conditions in many agricultural areas – drought, COVID-19, bushfires etc
- Investment in systems & targeted change in business mix to focus on higher value products & services driving **strong gross margin improvement**
- Strong **operating cash** conversion and **consistent dividend** payouts - balanced against capital requirements